Safety profile of orlistat: Results of a prescription-event monitoring study

International Journal of Obesity

Volumn 30, Issue 11, 2006, Pages 1645-1652

  Acharya, N V ^a   Wilton, L V ^a,b   Shakir, S A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Antiobesity agents; Observational studies; Orlistat; Pharmacovigilance; Postmarketing surveillance; Prescription event monitoring

Indexed keywords

CONTRACEPTIVE AGENT; FLUOXETINE; METHOTREXATE; TETRAHYDROLIPSTATIN;

ABDOMINAL PAIN; ADULT; AMNESIA; ANKLE INJURY; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMYELINATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERANCE; EAR DISEASE; EDEMA; ENDOCRINE DISEASE; ERYTHEMA; ERYTHEMA NODOSUM; EYE DISEASE; FECES INCONTINENCE; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HALLUCINATION; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEMATOMA; HEMIANOPIA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INCIDENCE; LABYRINTHITIS; LASSITUDE; LICHEN PLANUS; MALAISE; MALE; MENTAL DISEASE; METABOLIC DISORDER; METRORRHAGIA; MIGRAINE; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; OBESITY; OSTEOARTHRITIS; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RASH; RECTUM DISEASE; RESPIRATORY TRACT INFECTION; RETINA VEIN OCCLUSION; SIDE EFFECT; SKIN DISEASE; TREMOR; UNITED KINGDOM; UNPLEASANT DREAM; UNSPECIFIED SIDE EFFECT; URTICARIA; VAGINITIS; VITREOUS DISEASE; VOMITING; VULVITIS; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; ENGLAND; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LACTONES; MALE; MIDDLE AGED; OBESITY; PREGNANCY; PREGNANCY OUTCOME; PRIMARY HEALTH CARE; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME; VAGINITIS; WEIGHT LOSS; WITHHOLDING TREATMENT;

EID: 33750448005     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803323     Document Type: Article

References (27)

1. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993; 17: 241-244.
2. Royal College of Physicians Working Party. Overweight and Obese Patients: Principles of Management with Particular Reference to the Use of Drugs. The Royal College of Physicians: London, 1997.
3. Fricker J. Balancing the risks of anti-obesity pills. Lancet 1997; 349: 1374.
4. Roche Products Limited. Orlistat, Summary of Product Characteristics. August 1998.
5. Hollander P, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study. Diabet Care 1998; 21: 1288-1294.
6. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-172.
7. Shakir SA. PEM in the UK. In: Mann RD, Andrews E (eds). Pharmacovigilance. John Wiley & Sons Ltd: Chichester, UK, 2002, pp 333-344.
8. Stephens MDB (ed) Introduction. In: Detection of New Adverse Drug Reactions, 3rd edn, Macmillan Publishers Ltd: Great Britain, 1992, p 17.
9. Strom BL (ed) Sample size considerations for pharmacoepidemiology studies. In: Pharmacoepidemiology, 2nd edn, JohnWiley & Sons Ltd: UK, 1994; 29-38.
10. Machin D, Campbell MJ, Fayers PM, Pinol APY. Sample Size Tables for Clinical Studies, Table 7.1, Blackwell Science Ltd: Oxford, UK, 1997, pp 143-150.
11. Machin D, Campbell MJ, Fayers PM, Pinol APY. Sample Sizes for Clinical Studies, Table 7.2, Blackwell Science Ltd: Oxford, UK, 1997, pp 143-153.
12. International Ethical Guidelines for Biomedical Research Involving Human Subjects. CIOMS/WHO: Geneva, 1993.
13. Guidelines on the Practice of Ethical Committees in Medical Research involving Human Subjects. Royal College of Physicians of London. August 1996.
14. Multi-Centre Research Ethics Committees Guidance Notes. October, 19 (Appendix C). 2000. Ref Type: Generic [http://www.corec. org.uk/wordDocs/ guideNotes.doc - page 19 Appendix C].
15. General Medical Council. General Medical Council booklet Confidentiality: Protecting and Providing Information; Frequently Asked Questions Q7, p9, 2004..
16. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ('black triangle') drugs in general practice: observational study. BMJ 1998; 317: 119-120.
17. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 358: 1872-1873.
18. Roche Products Ltd. Orlistat - Summary of Product Characteristics 24 September 2004.
19. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999; 69: 1108-1116.
20. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805-875.
21. Mikhail N, Golub MS, Tuck ML. Obesity and hypertension. Prog Cardiovasc Dis 1999; 42: 39-58.
22. Persson M, Vitols S, Yue Q-Y. Orlistat associated with hypertension. BMJ 2000; 321: 87.
23. Huber MH. Roche concludes that there is no evidence of a causal association (letter). BMJ 2001; 322: 110.
24. Persson M, Vitols S, Yue Q-Y. Author's reply (letter). BMJ 2001; 322: 110.
25. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003; 27: 1437-1446.
26. Leung WY, Neil Thomas G, Chan JC, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003; 25: 58-80.
27. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (Xendos) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabet Care 2004; 27: 155-161.